Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
Study of Quality of Life, Safety and Compliance During Treatment of Schizophrenia or Bipolar Affective Disorder, in Patients Using the Drug Kvepin® (Quetiapine) as Monotherapy or Combination Therapy With Other Antipsychotics (Ispitivanje Kvalitete života, Sigurnosti i Saradljivosti u Toku liječenja Shizofrenije Ili Bipolarnog Afektivnog poremećaja, Kod Pacijenata Koji Koriste Lijek Kvepin® (Kvetiapin) Kao Monoterapiju Ili Kombinovanu Terapiju sa Drugim Antipsihoticima)
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in combination with another antipsychotic/antipsychotics. The main outcome measures are:
- quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL)
- safety through the monitoring of the incidence of possible adverse drug events by the researcher, with the assessment of the association between the administration of the drug and the occurrence of an adverse reaction
- therapy adherence using the Medication Adherence Rating Scale (MARS).
The subjects will be divided into two groups:
-
Newly diagnosed patients with a diagnosis of schizophrenia or bipolar affective disorder whose individual therapeutic approach, based on the clinical assessment of the research physician, includes one of the following therapies:
- monotherapy with the drug quetiapine
- combined antipsychotic therapy with quetiapine and aripiprazole
- combined antipsychotic therapy with quetiapine and haloperidol
-
Patients with a diagnosis of schizophrenia or bipolar affective disorder who are on therapy with one of the antipsychotics (aripiprazole or haloperidol), and who, based on the clinical assessment of the investigator, require adjunctive quetiapine therapy. This group will include two subgroups of patients:
- combined antipsychotic therapy with quetiapine and aripiprazole
- combined antipsychotic therapy with quetiapine and haloperidol Recruitment of subjects will be carried out by physicians/researchers based on the patient's history and diagnosis. The diagnosis of schizophrenia or bipolar affective disorder will be based on the standard diagnostic criteria in medical practice (validated measurement scales in psychiatry - Young's Mania Scale, Beck Depression Scale and PANNS Schizophrenia Scale).
Patients will have four visits to physician/researcher:
- First visit - baseline at which patient will be included in the study
- Second visit - 4 months after the baseline
- Third visit - 8 months after the baseline
- Fourth visit - 12 months after the baseline
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Halima Karakaš
- Telefonní číslo: +38762478535
- E-mail: HalimaK@Bosnalijek.ba
Studijní záloha kontaktů
- Jméno: Una Glamoclija, PhD
- Telefonní číslo: +38761147401
- E-mail: UnaG@Bosnalijek.ba
Studijní místa
-
-
-
Sarajevo, Bosna a Hercegovina, 71000
- Nábor
- Clinic of Psychiatry, University Clinical Center of Sarajevo
-
Kontakt:
- Gorana Sulejmanpašić, PhD
- Telefonní číslo: +38733297359
- E-mail: psihijatrija@kcus.ba
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Schizophrenia or bipolar affective disorder patients of both sexes aged 18 to 65 years.
Popis
Inclusion Criteria:
- Persons over 18 years of age and under 65 years of age.
- Schizophrenia or bipolar affective disorder established by the usual diagnostic criteria applied in a psychiatric clinic or hospital ward/unit within the clinic or outpatient.
- Patients who are treated as outpatients, inpatients or have been discharged from the clinic/hospital with a recommendation for quetiapine monotherapy or combination therapy of quetiapine with aripiprazole or haloperidol. Recommended by a specialist psychiatrist/neuropsychiatrist in clinical and hospital centers and through specialist-consultant outpatient clinics in Bosnia and Herzegovina.
Exclusion Criteria:
- Persons younger than 18 years and older than 65 years
- Hypersensitivity to the components of the drug
- Positive history of angioneurotic edema
- Pregnancy
- Breastfeeding
- Simultaneous use with cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors, azole antifungals, erythromycin, clarithromycin and nefazodone
- Patients who are planning to become pregnant in the near future
- Diagnosed medical conditions that may constitute a contraindication for the use of the drug quetiapine
Withdrawal Criteria:
- Deterioration of the underlying disease that requires therapy discontinuation
- Development of serious adverse events requiring therapy discontinuation
- Occurence of pregnancy
- Development of another disease that affects the course of the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Newly diagnosed patients
Newly diagnosed patients with a diagnosis of schizophrenia or bipolar affective disorder |
Monotherapy with the drug quetiapine Combined antipsychotic therapy with quetiapine and aripiprazole Combined antipsychotic therapy with quetiapine and haloperidol |
|
Previously diagnosed patients
Patients with a previous diagnosis of schizophrenia or bipolar affective disorder |
Combined antipsychotic therapy with quetiapine and aripiprazole Combined antipsychotic therapy with quetiapine and haloperidol |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Measurement of quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL)-BREF
Časové okno: 12 months from inclusion into the study (baseline)
|
Evaluation of the quality of life of patients during treatment for schizophrenia or bipolar affective disorder using monotherapy with the drug quetiapine or combination therapy with the drug quetiapine and another antipsychotic (aripiprazole or haloperidol). World Health Organization Quality of Life questionnaire (WHOQOL)-BREF will be used. It consists of 26 items that evaluate an individual's perception of their quality of life and consists of four domains: physical health (e.g., pain, energy, sleep, mobility, activities of daily living, work capacity); psychological health (e.g., positive and negative feelings, self-esteem, body image, cognition, spirituality); social relationships (e.g., personal relationships and social support) and environment. Domain scores are calculated according to the WHO scoring guidelines and can be transformed to a 0-100 scale, where higher scores represent a better quality of life. |
12 months from inclusion into the study (baseline)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Safety assessment through incidence of possible adverse drug events and evaluation of the association between the administration of the drug and the occurrence of an adverse reaction
Časové okno: 12 months from baseline
|
Safety through the monitoring of the incidence of possible adverse drug events by the researcher, with the assessment of the association between the administration of the drug and the occurrence of an adverse reaction |
12 months from baseline
|
|
Therapy adherence using the Medication Adherence Rating Scale (MARS)
Časové okno: 12 months from baseline
|
Medication Adherence Rating Scale (MARS), a validated self-report questionnaire designed to evaluate patients' adherence to prescribed medication regimens. The instrument was originally developed for patients receiving long-term pharmacological treatment and has been widely used in studies of psychiatric and chronic medical conditions. The MARS consists of 10 items that assess both medication-taking behavior and patients' attitudes toward medication, including forgetfulness, intentional omission of doses, discontinuation of treatment when feeling better or worse, and beliefs regarding the effects of medication. Responses are provided in a dichotomous (Yes/No) format. Individual item scores are summed to obtain a total score ranging from 0 to 10, with higher scores indicating better medication adherence. The scale enables the identification of both intentional and unintentional non-adherence and provides insight into factors affecting treatment adherence. |
12 months from baseline
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Gorana Sulejmanpašić, PhD, Clinic of Psychiatry, University Clinical Center of Sarajevo
- Vrchní vyšetřovatel: Amra Memić Serdarević, PhD, Clinic of Psychiatry, University Clinical Center of Sarajevo
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Bipolární a příbuzné poruchy
- Schizofrenní spektrum a jiné psychotické poruchy
- Duševní poruchy
- Poruchy nálady
- Schizofrenie
- Bipolární porucha
- Sloučeniny síry
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, 2-prsten
- Heterocyklické sloučeniny, fúzované kroužek
- Chinolony
- Chinoliny
- Heterocyklické sloučeniny, 3-kroužek
- Butyrofenony
- Ketony
- Piperaziny
- Dibenzothiazepiny
- Thiazepiny
- Thiepiny
- Aripiprazol
- Quetiapin fumarát
- Haloperidol
- Farmaceutické přípravky
Další identifikační čísla studie
- KVP-01-2024
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .